About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Oncotarget
›
Top Articles
Oncotarget
Oncology
3.2
(top 5%)
Impact Factor
3.5
(top 5%)
extended IF
152
(top 2%)
H-Index
20.6K
authors
24.9K
papers
561.5K
citations
8.3K
citing journals
249.1K
citing authors
Most Cited Articles of Oncotarget
Title
Year
Citations
Inflammatory responses and inflammation-associated diseases in organs
2018
1.2K
Combination therapy in combating cancer
2017
765
Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients
2016
633
Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/β-catenin pathway
2015
530
The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer
2015
470
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health
2011
454
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
2012
435
Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer
2014
412
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
2016
353
EMT, CTCs and CSCs in tumor relapse and drug-resistance
2015
346
Emerging roles of circRNA_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer
2016
333
Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival
2010
328
Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers
2011
326
Recent developments in targeting carbonic anhydrase IX for cancer therapeutics
2012
324
GSK-3 as potential target for therapeutic intervention in cancer
2014
321
An emerging function of circRNA-miRNAs-mRNA axis in human diseases
2017
319
The molecular mechanisms of chemoresistance in cancers
2017
311
Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway
2015
310
Prognostic and predictive value of PDL1 expression in breast cancer
2015
305
Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a
2014
304
Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease
2015
303
Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease
2015
303
Aldehyde dehydrogenase 1A1 in stem cells and cancer
2016
297
Classification of current anticancer immunotherapies
2014
296
The regulation of β-catenin activity and function in cancer: therapeutic opportunities
2017
294
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.